Harvard Bioscience, Inc.
HBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -16.1% | -1% | -4.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 58.2% | 58.9% | 53.7% | 56.9% |
| EBITDA | -$0 | $0 | $0 | $0 |
| % Margin | -1.6% | 7.2% | 0.8% | 7.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -13.2% | -3% | -8.4% | -0.2% |
| EPS Diluted | -0.28 | -0.081 | -0.23 | -0.007 |
| % Growth | -247.8% | 65% | -3,139.4% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |